Q1 2027 Aurobindo Pharma Ltd Earnings Call Transcript
Key Points
- Consolidated revenues increased 16% year-on-year to INR9,150 crores, driven by broad-based growth across all business areas.
- Operating EBITDA margin stood at a strong 21%, with gross margin improving to 60.4% from 58.8% in the prior year.
- Successfully completed the Lannett acquisition, enhancing the US platform and expanding presence in complex and controlled substances.
- Europe business delivered 11% constant currency growth, with EBITDA margin reaching 20%.
- Biosimilar pipeline progressing well, with multiple filings expected in the US and Europe, and TheraNym CMO on track for revenue from 2028.
- US business growth was modest at 8.1% year-on-year, reflecting a mature base business.
- UGA injectables business expected to see only single-digit growth due to lack of new approvals and ongoing remediation at Unit 3.
- China OHD facility, while ramping up, is still not profitable, with EBITDA expected to turn positive only this year.
- R&D expenses remain elevated at INR344 crores, though slightly lower than the prior year.
- Geopolitical issues, particularly in the Middle East, could impact future performance and margin targets.
(Operator Instructions) Please note this conference is being recorded.
I now hand over the conference to Mr. Varun Mali. Thank you, and over to you, sir.
Thank you, Vandit. Good morning, ladies and gentlemen, and welcome to our first quarter FY27 earnings call. I'm Varun Mali from the Investor Relations and Corporate Communications team.
We hope you have received the Q1 FY27 financials and the press release that was sent out yesterday. These are also available on our website www.aurobindo.com.
Would now like to introduce our senior management team who is on the call with us today, represented by Dr. Satakarni Makkapati, CEO, Aurobindo Biosimilars Vaccines and Peptide Businesses and Director, Aurobindo Pharma Limited; Mr. Yugandhar Puvvala, CEO, UGA Pharma Specialties Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma USA; Mr. V. Muralidharan, CEO, Europe Formulations Business; Mr. S
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
